Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07186946 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants
A Phase 1 study, sponsored by Thryv Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07186946 is a Phase 1 study that has completed, run by Thryv Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT07186946, a Phase 1 study, has completed, sponsored by Thryv Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
A research study that involves the use of an investigational drug called THRV-1268. The main purpose is to measure the safety (whether it causes any side effects) and tolerability (if it does cause any side effects, how well your body is able to handle them) in healthy obese adults. This study will also look at how the drug moves through the body, is absorbed, distributed, metabolized and eliminated.
Interventions
- DRUG Placebo
- DRUG THRV-1268
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2025-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07186946
The ClinicalTrials.gov registry entry for NCT07186946 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thryv Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07186946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07186946 about?
NCT07186946 is a clinical study titled "Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants". A research study that involves the use of an investigational drug called THRV-1268. The main purpose is to measure the safety (whether it causes any side effects) and tolerability (if it does cause any side effects, how well your body is able to handle them) in healthy obese adults. This study will ...
What is the current status of trial NCT07186946?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-09-15. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT07186946?
The interventions under investigation include: Placebo (DRUG), THRV-1268 (DRUG).
Who is sponsoring clinical trial NCT07186946?
This trial is sponsored by Thryv Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.